This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D76.1 | Synonyms: HLH, Hemophagocytic syndrome, Macrophage activation syndrome (MAS)
Hemophagocytic lymphohistiocytosis (HLH) was first described in 1952 by Scott and Robb-Smith. They described a pathological syndrome with a fatal course accompanied by histiocytic proliferation and hemophagocytosis as "histiocytic medullary reticulosis." Later, in 1979, Farquhar and Claireaux described a fatal histiocytosis occurring in siblings and proposed the name "familial haemophagocytic reticulosis (FHL)."
In the 1980s–1990s, many cases of secondary HLH associated with infection, autoimmune disease, and malignancy were reported, and HLH came to be recognized as a clinical syndrome of immune dysregulation rather than a simple genetic disease. In 1991, the Histiocyte Society first proposed diagnostic criteria for HLH, and in 1994 the HLH-94 protocol was established, setting a standard treatment centered on dexamethasone and etoposide.
In Korea, pediatric HLH cases began to be systematically reported in the late 1990s. Since the 2000s, as awareness of adult HLH has grown, multidisciplinary collaboration across hematology-oncology, pediatrics, rheumatology, infectious diseases, and other departments has been strengthened.
Primary HLH is caused by mutations in genes involved in the cytotoxic function of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Representative causative genes include perforin (PRF1), MUNC13-4 (UNC13D), Syntaxin 11 (STX11), MUNC18-2 (STXBP2), and RAB27A; variants in these genes block the secretory pathway of lytic granules, so CTL and NK cells lose their ability to kill target cells. Most primary HLH follows an autosomal recessive mode of inheritance.
The main causes of secondary HLH are as follows. Infectious: Epstein-Barr virus (EBV) is the most common; cytomegalovirus (CMV), influenza, HIV, Mycobacterium tuberculosis, and others are also causes. Autoimmune/autoinflammatory: presents as giant cell activation syndrome (MAS) accompanying systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus (SLE), adult-onset Still's disease, and others. Malignancy: occurs as a complication of T-cell lymphoma, NK-cell lymphoma, acute leukemia, and others.
The genetic causes of primary HLH are broadly classified into two groups. Among the familial types classified as FHL1–5, FHL2 is caused by mutations in the PRF1 (perforin 1) gene (10q22), FHL3 by mutations in the UNC13D gene (17q25), FHL4 by mutations in the STX11 (6q24) gene, and FHL5 by mutations in the STXBP2 (19p13) gene. All of these follow an autosomal recessive mode of inheritance. HLH associated with immunodeficiency syndromes includes Chediak-Higashi syndrome (LYST gene), Griscelli syndrome type 2 (RAB27A gene), Hermansky-Pudlak syndrome type 2 (AP3B1 gene), and others.
PRF1 mutations (FHL2) account for about 30–50% of all primary HLH, and the p.A91V polymorphism in particular may act as a predisposition to HLH in adults. UNC13D mutations (FHL3) are reported relatively frequently in East Asian populations, including Korea, Japan, and China. In those with compound heterozygous mutations, the phenotype can vary.
HLH is a rare disease; the incidence of primary HLH is estimated at about 1–2 per million newborns. A survey in Sweden found a pediatric HLH incidence of about 1.2 per million children per year. Secondary HLH occurs more frequently in ICU patients, immunosuppressed patients, and patients with hematologic malignancies.
Primary HLH mainly develops in infants and children, with more than 80% presenting within the first year of life. However, it has also been reported in adults, and adult HLH is mostly due to secondary causes (infection, malignancy, autoimmunity). There is no clear sex difference.
In Korea, a substantial proportion of pediatric HLH patients are associated with EBV infection, consistent with the high frequency of EBV-associated HLH in East Asia. Adult HLH is also mainly associated with EBV and hematologic malignancies, and dozens of new diagnoses per year are reported at Korean university hospitals.
Normally, CTL and NK cells kill target cells (virus-infected cells, tumor cells) by secreting lytic granules containing perforin and granzymes into the immunological synapse with the target cell. In HLH this process is blocked, so target cells are not killed, and the interaction between antigen-presenting cells (APC) and T cells is persistently maintained.
Because of defective cytotoxic function, activated T cells and macrophages proliferate excessively, and large amounts of inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-10, IL-12, and IL-18 are secreted. IFN-γ in particular is the key mediator of macrophage activation; activated macrophages form a positive feedback cycle through hemophagocytosis and further cytokine secretion. This "cytokine storm" is the core mechanism of multiorgan failure.
Activated histiocytes/macrophages phagocytose blood cells, including red blood cells, white blood cells, and platelets, in the bone marrow, spleen, and lymph nodes, causing pancytopenia. This is the key pathological finding from which the disease takes its name.
Persistent high fever (38.5℃ or higher) is the earliest and most common symptom of HLH; fever lasting days to weeks that does not respond to antibiotics is characteristic.
Pancytopenia causes pallor, fatigue, and a bleeding tendency (petechiae, ecchymoses, epistaxis, gastrointestinal bleeding). Susceptibility to infection increases, and secondary infections may occur.
Splenomegaly is a key symptom of HLH and is sometimes accompanied by tenderness. Lymphadenopathy is also commonly observed.
In primary HLH and some secondary HLH, seizures, altered consciousness, meningeal irritation, and symptoms of raised intracranial pressure may occur. Nervous system involvement is an important factor that worsens prognosis.
On physical examination, splenomegaly (splenic tip 3 cm or more below the costal margin) and hepatomegaly are the main signs. Along with fever, lymphadenopathy, skin rash, and jaundice may be present. With nervous system involvement, neck stiffness, decreased consciousness, and focal neurological deficits may occur.
| Test item | Findings | Reference value |
|---|---|---|
| Hemoglobin (Hb) | Decreased | <9 g/dL |
| Platelets | Decreased | <100×10³/μL |
| Neutrophils | Decreased | <1×10³/μL |
| Serum ferritin | Markedly elevated | >500 ng/mL (often >10,000) |
| Triglycerides | Elevated | ≥3.0 mmol/L |
| Fibrinogen | Decreased | <1.5 g/L |
| Soluble CD25 | Markedly elevated | ≥2,400 U/mL |
| NK cell activity | Decreased or absent | — |
Bone marrow aspiration and biopsy show hemophagocytosis by histiocytes. Abdominal ultrasound or CT may show hepatosplenomegaly and ascites. On brain MRI, T2 hyperintense lesions and ventricular enlargement may be evidence of nervous system involvement.
The HScore is a clinical tool that scores the likelihood of HLH; it sums 9 items—fever, splenomegaly, cytopenias, ferritin, triglycerides, fibrinogen, bone marrow hemophagocytosis, AST, and underlying immunodeficiency—to calculate the probability of HLH. A score of 169 or higher is reported to correspond to a 93% probability of HLH.
Serum ferritin >500 ng/mL is a nonspecific screening marker for HLH, whereas >10,000 ng/mL is highly specific for HLH. In ICU patients and patients with fever of unknown origin, an unexplained extreme rise in ferritin should raise strong suspicion of HLH.
Perform HLH screening tests immediately when there is a family history of primary HLH, when an infant has fever with pancytopenia, or when the clinical condition deteriorates rapidly after EBV infection.
According to the Histiocyte Society HLH-2004 criteria, HLH is diagnosed when 5 or more of the following 8 items are met or when a molecular genetic diagnosis is confirmed.
NGS panel testing of HLH-related genes such as PRF1, UNC13D, STX11, and STXBP2. Flow cytometry to confirm perforin protein expression. Diagnosis is confirmed when a primary HLH gene mutation is identified.
Viral testing for EBV, CMV, HSV, HIV, and others (PCR, serology). Autoimmune antibody testing (ANA, anti-dsDNA, RF, etc.). Bone marrow biopsy and lymph node biopsy to exclude malignancy.
The standard treatment for primary and severe secondary HLH is the HLH-94/2004 protocol, consisting of 8 weeks of induction therapy. It is based on dexamethasone (high dose, tapering regimen) and etoposide (VP-16, twice weekly → once weekly), with intrathecal methotrexate (IT-MTX) added when the central nervous system is involved.
The only curative treatment for primary HLH is allogeneic hematopoietic stem cell transplantation (allo-HSCT). If no HLA-matched sibling donor is available, an unrelated donor or haploidentical transplant is performed. Reduced-intensity conditioning (RIC) transplantation is reported to reduce the toxicity of standard transplantation while being equally effective.
Treating the underlying disease is central in secondary HLH. For EBV-associated HLH, EBV antiviral treatment is considered along with the HLH-94/2004 protocol. For MAS (giant cell activation syndrome), high-dose steroids, cyclosporine, anakinra (an IL-1 receptor antagonist), and similar agents are used first.
The IFN-γ monoclonal antibody emapalumab received US FDA approval (2018) for primary HLH and is used for primary HLH that is refractory to or relapses after conventional therapy. The JAK1/2 inhibitor ruxolitinib is also under clinical investigation.
Without treatment, HLH is fatal in almost all cases, with a reported median survival of less than 2 months. Multiorgan failure, bleeding, and central nervous system involvement are the direct causes of death.
With the HLH-94/2004 protocol, the 5-year survival rate is reported to be about 54–64%. The 5-year survival rate after hematopoietic stem cell transplantation for primary HLH is about 60–70%. Central nervous system involvement, delayed diagnosis, and incomplete response to induction therapy are poor prognostic factors.
Serum ferritin level at diagnosis, central nervous system involvement, EBV viral load, and response to initial treatment are the key factors determining prognosis.
Genetic testing is performed in family members (especially siblings) of patients with primary HLH to identify early whether they carry the same mutation or are affected. Thorough genetic counseling for carrier parents and prenatal diagnosis in subsequent pregnancies are recommended.
In immunosuppressed patients after transplantation, monitor for viruses such as EBV and CMV and provide prophylactic antiviral therapy. In patients with autoimmune diseases, recognize prodromal symptoms of MAS (sudden fever, rapid rise in ferritin) early and intensify treatment.
The prognosis of HLH depends greatly on the timing of diagnosis and treatment initiation. HLH should be included early in the differential diagnosis of any patient with a combination of fever of unknown origin, cytopenias, splenomegaly, and hyperferritinemia.